Qitaihe, China

Kun Hu

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Scinopharm Taiwan, Ltd.. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kun Hu. Retrieved from https://idiyas.com/inventor/kun-hu-cq5f9q89

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kun Hu: Innovator in Pharmaceutical Synthesis

Introduction

Kun Hu is an accomplished inventor based in Qitaihe, China, recognized for his significant contributions to the field of pharmaceutical synthesis. His work has led to the development of innovative methods that enhance the production efficiency of important compounds used in medical treatments.

Latest Patents

Kun Hu holds a patent for the "Synthesis of Decitabine," which outlines a method for producing a β-enriched protected decitabine. This patent is a testament to his dedication to advancing pharmaceutical solutions and improving drug formulation processes.

Career Highlights

As a key player at Scinopharm Taiwan Ltd., Kun Hu has applied his expertise in synthetic methodology to ensure that the company remains at the forefront of pharmaceutical innovation. His singular focus on drug synthesis has allowed him to make notable strides within the industry, reflected by his successful patent.

Collaborations

Kun has collaborated with esteemed colleagues such as Julian Paul Henschke and Xiaoheng Zhang. Together, they have contributed to a dynamic work environment aimed at advancing the field of medicinal chemistry and pharmaceutical development.

Conclusion

In conclusion, Kun Hu stands as a notable figure in the realm of pharmaceuticals, particularly through his inventive contributions to the synthesis of vital compounds. His work not only enhances production methodologies but also positions him as a significant asset in the ongoing evolution of drug development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…